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Response to Treatment with Interferon-alpha and Ribavirin in Patients with Chronic Hepatitis C
Virus Genotypes 2 and 3 Depends on the Degree of Hepatic Fibrosis
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The combined therapy with interferon alfa plus ribavirin (INF+RBV) is considered the most
appropriate treatment for patients with chronic hepatitis C virus genotypes 2 and 3 in Brazil. However,
wide variations in the rates of sustained viral response (SVR) have been reported among such
patients.  We evaluated, retrospectively, factors associated with SVR in subjects with chronic hepatitis
C virus genotypes 2 and 3 and that received medication from the Health Secretariat of the state of São
Paulo. One-hundred-seventy-seven consecutive patients with chronic hepatitis C were treated for 24
or 48 weeks according to the viral genotype. Patients co-infected with associated hepatic diseases or
who had problems with alcohol abuse were excluded. The genotype of the HCV-RNA was identified
through restriction analysis, the viral load through quantitative PCR (Amplicor, Roche) and the
degree of hepatic fibrosis according to the Metavir score. Demographic, virological and histological
parameters were submitted to binary logistic regression analysis to identify the variables associated
with SVR. The overall rate of SVR was 36.4% for the 177 patients, and genotype 2 or 3 was the main
parameter independently associated with SVR. Among the 77 patients with these viral genotypes,
only the stage of fibrosis had a significant effect on the SVR (odds ratio (OR) = 3.035; 95% CI
(confidence interval) = 1.196-7.699; p=0.019). The rate of SVR among the subjects with fibrosis at an
advanced stage (F3-F4) was 38%, compared to 75% for patients with fibrosis at an initial stage (F0-
F2). Consequently, other therapeutic options should be considered for patients with genotypes 2 and
3 who have advanced fibrosis.
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fibrosis.
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Combined treatment with interferon alfa (INF-α) plus
ribavirin (RBV) has revolutionized the therapy of chronic
hepatitis caused by the hepatitis C virus (HCV) [1-2]. However,
with the introduction of pegylated INF, which has greater
therapeutic efficacy, is easier to use, and has a lower incidence
of side effects [3-5], the combined treatment of pegylated INF
plus RBV has become the chosen therapy for infected subjects
in several developed countries [6,7]. Unfortunately, the high
cost of this medicine has limited its use in replacing
conventional  INF-α. In some countries, such as Brazil, the
option has been to limit the use of this medicine to naive
subjects with genotype 1 chronic C hepatitis. This option is
due to the significantly higher rates (60% to 70%) of sustained
virological response (SVR) that can be obtained with the use
of INFa in carriers of genotypes 2 and 3 [1,2].
Various retrospective analyses conducted in Brazil have
shown contrasting results for the SVR rates found in carriers
of HCV genotypes 2 and 3 who have chronic hepatitis and are
treated with combined INF-α+RBV [8,9]. On the other hand,
studies on the retreatment of such non-responder and relapser
patients reported high levels of SVR when pegylated INF-
α+RBV was used [10].
We conducted a retrospective analysis of the factors
associated with SVR in subjects with genotypes 2 and 3 who
had chronic C hepatitis and had been treated with
conventional therapy (INF-α+RBV).
Material and Methods
We included consecutive adult patients with chronic
hepatitis C virus, with detectable HCV-RNA in the peripheral
blood detected by PCR, who received a combined therapy of
INF-α+RBV, which was provided by the Health Secretariat of
the state of São Paulo from July of 1999 to December 2003.
Subjects were treated for 24 to 48 weeks, according to a
protocol defined by the Secretariat and international
guidelines [1,2]. Patients with other associated hepatic
diseases, co-infected with HBsAg, HIV, active alcohol drinkers
during the previous six months, or with contraindications to
the use of INF and/or RBV were excluded from our study.
Aspartate-aminotransferase (AST) and alanine-
aminotransferase (ALT) serum concentrations were
determined through the automatic kinetic method. The
genotype of the HCV-RNA was identified through restriction
analysis of the amplified sequences of the non-coding 5’
region. The viral load was determined with the quantitative
PCR method (Cobas Amplicor, Roche Diagnostics).
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The stage of the hepatic lesion was determined by
evaluating fragments from percutaneous hepatic biopsies
stained with hematoxylin and eosin (HE), reticulin and
Masson’s trichrome, and by applying the Metavir criteria (11),
where F0 = absence of fibrosis, F1 = fibrous portal expansion,
F2 = portal fibrosis with incomplete septa, F3 = bridging
fibrosis, and F4 = cirrhosis.
Intention-to-treat analysis was used, and the response to
the treatment was evaluated; this was determined by a
sustained virological response (SVR), indicated by
undetectable levels of HCV-RNA in the peripheral blood 24
weeks after ending the treatment. The data obtained was
presented as a percentage or as a mean ± standard deviation.
Statistical analysis was conducted by binary logistic regression
to identify the independent variables associated with response
to treatment, which was considered as a dependent variable.
The variables were categorized according to previously-
established criteria [1,2], which were: age (< or ≥ 40 years),
gender (male or female); genotype (1a/1b x 2,3), viral load (< or
≥ 850,000 IU), and stage (F0-F2 x F3-F4).
The level of significance was set at <0.05 (5%) for all
statistical analyses [12].
Results
One-hundred-seventeen subjects were evaluated in our
study. The demographic, virological, biochemical and
histopathological characteristics are shown in Table 1. Of the
117 patients, 19 showed clinical, ultrasonography and
endoscopy signs compatible with hepatic cirrhosis; because
of alterations in their blood clotting ability, no biopsies were
performed. Most of the subjects had viral genotypes 1a or 1b,
were males, with elevated hepatic enzymes, had a viral load
below 850,000 IU/mL and showed fibrosis at an advanced
stage on hepatic biopsy.
Overall, 36.4% of the subjects showed SVR to the treatment
with INF-α+RBV. The parameters that were independently
associated with the response to treatment were genotypes 2
and 3 and a low stage of fibrosis, F0-F2 (Table 2).
The factors involved in the SVR of the subjects with
genotypes 2 and 3 were evaluated. Only the stage of fibrosis
appeared to significantly influence SVR (Table 3). The rates
of SVR were 75.7% for subjects with fibrosis at the initial
stage (F0 to F2), and 38.6% for those with bridging fibrosis or
cirrhosis (Figure 1).
The rate of discontinuation of treatment due to side effects
did not differ between genotype 2 and 3 patients with
advanced fibrosis compared to those with initial staging (16%
x 9%, p=0.574)
Discussion
Treatment of chronic hepatitis C virus with pegylated INF-
α, combined with RBV, which has greater therapeutic efficacy
Treatment of Chronic Hepatitis C Genotype 2 and 3
Table 1. Demographic, biochemical, virological and
histopathological characteristics of the subjects with chronic
hepatitis C virus
Table 2. Logistic regression analysis of the demographic,
virological and histopathological parameters in subjects with
chronic hepatitis C virus submitted to treatment with  interferon
alfa plus ribavirin
Table 3. Logistic regression analysis of data on patients with
chronic hepatitis C virus genotypes 2 and 3 (n= 77), evaluating
the parameters associated with a sustained viral response in
patients treated with interferon alfa plus ribavirin.
Figure 1. Virological response to treatment with interferon
alpha and ribavirin in patients with chronic hepatitis C,
genotypes 2 and 3, according to the fibrosis staging. RVS:
sustained virological response. NON RESP: non responders.
Characteristics N=177
Age (years) 48.1 ± 11.9
Male gender 69.9% (121:52)
ALT (x ULN) 3.61 ± 6.89
Genotype 1a/1b 56.5% (100: 77)
Viral load < 850,000 IU/mL 60.0% (106:71)
Structural F3, F4 59.3% (105:72)
ULN = upper limit of normality; IU = international
units; ALT = alanine aminotransferase.
Parameter RR 95% CI P
Structural (F0-F2 x F3,F4) 4.536 2.194-9.380 <0.001
Genotype (2,3 x 1) 5.575 2.680-11.598 <0.001
Age, gender, genotype, viral load, and stage (fibrosis) parameters
were included in the regression analyses. RR = relative risk
Parameter RR 95%CI P
Age (< or ≥ 40 years) 1.017 0.974-1.062 0.440
Gender (male:female) 0.916 0.640-5.865 0.242
Viral load (< or ≥850,000 IU/mL) 0.972 0.669-4.891 0.243
Structural (F0-F2 x F3, F4) 3.297 1.317-8.256 0.011*
CI = confidence interval. * = significant.
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than unpegylated INF-α, is easier to use, and has a lower
incidence of side effects [3-5]  has become the chosen therapy
for subjects infected with this virus in several developed
countries [5-6]. On the other hand, conventional INF-α is an
economically viable alternative for developing countries with
significant portions of their populations infected with this
virus. However, the cost-benefit analysis needs to be
considered, especially in the case of patients that do not
respond to an initial treatment, who could require a second or
third treatment, or where the disease could progress to a more
advanced forms, which would increase the overall cost of
treatment. Therefore, it is necessary that the treatment cost
take into account the optimization of results, especially in
Brazil, where the medicines provided by the Heath Secretariat
vary in potency, depending on their commercial origin.
Even in the classic studies on the use of INF-α+RBV, traits
such as age and gender of the subject, the viral load, the HCV-
RNA genotype, and the stage of fibrosis observed through
hepatic biopsy [1,2,13], were known to be predictive factors
for the response of patients to treatment. Based on the
evaluation of the 117 cases, only the genotype and structural
alteration (stage of the fibrosis) were found to be independent
factors associated with response to treatment. These results
are similar to those found by Pariente et al. [13], who made a
similar study. Thus, we conclude that clinical and virological
factors associated with the response to the combined
treatment have different influences. In the ‘a la Carte’ treatment
proposed by Poynard et al. [14], the same importance is given
for all five predictive variables associated with SVR (age,
gender, viral load, genotype and stage of structural lesion).
These factors are known to have different impacts, with
genotype being the most important factor in all casuistic
studies and the one that shows the highest odds ratios, even
in studies with pegylated INF [1-5,13-15]. The larger the group
analyzed, the greater the chance of identifying other factors
that have a small impact.
The analysis of subjects with genotypes 2 and 3 who had
chronic C hepatitis showed that the only factor that could be
associated with SVR was the stage of fibrosis observed in the
hepatic biopsy. This result was expected since the regression
analysis of the 177 patients identified this structural alterations
as an response factor independent from the genotype.
The importance of the stage of fibrosis in SVR to treatment
with INF-α+RBV has been documented in many studies
[13,14,16,17]. Several factors could be associated with the low
response observed in subjects who have advanced stage
fibrosis. These could include a greater prevalence of side
effects and the need to reduce the dosage of medications;
even viral kinetics appears to be different in patients with
more advanced fibrosis [16,18].
In addition, our study allowed some insight on the
discrepancies found in the success of treatment of patients
with genotypes 2 and 3 in Brazil, who have a widely ranging
rate of SVR (between 20 and 80%) [8,9]. These discrepancies
may be a function of the spectrum of the case study. Medical
groups working in hepatitis C reference centers primarily attend
patients with initial stages of the disease, who will attain more
favorable results, when compared to a Liver Unit, which has
the tendency to work with the disease at more advanced stage
[19,20].
The SVR values of around 40% found in our study are
close to those reported in 2003 at the European Congress of
Hepatic Diseases (EASL). An evaluation of the therapeutic
response to the treatment with pegylated INF-α+RBV was
conducted in subjects with fibrosis at an advanced stage, in a
multicenter study. A group treated with INF+RBV during 48
weeks was the control. The authors found SVR in 45% of the
subjects in the control group and in 75% of the patients
treated with pegylated INF-α, independent of the dosage of
RBV and the period of treatment [21]. These data suggest that
the use of pegylated INF-α doubles the therapeutic response
in these subjects.
These results raise a serious question about the decision
to generalize a treatment based only on the viral genotype,
without considering the individual differences of subjects.
Even though the number of patients in our study was small
when compared to international studies, an important variance
in response was caused by differences in the hepatic staging
of the disease, indicating that this factor is an important
variable.
Therefore, our data indicate that in Brazil, subjects with
chronic hepatitis due to HCV genotypes 2 or 3 and who have
a low degree of fibrosis are ideal candidates for treatment with
INF-α+RBV. On the other hand, patients with advanced stage
fibrosis had low rates of response to this combined therapy,
and a criterion of treatment with pegylated interferon as a first
alternative should be considered.
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